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Abstract
Background: Sleep-related investigations in acute myocardial infarction (AMI) patients are rare. The aim of this
study was to examine sex-specific associations of patient-reported sleep disturbances within 4 weeks before AMI
and long-term survival.
Methods: From a German population-based, regional AMI registry, 2511 men and 828 women, aged 28–74 years,
hospitalized with a first-time AMI between 2000 and 2008 and still alive after 28 days, were included in the
study (end of follow-up: 12/2011). Frequency of any sleep disturbances within 4 weeks before AMI was inquired by a
6-categorical item summarized to ‘never’, ‘sometimes’ and ‘nightly’. Cox regression models were calculated.
Results: Over the median follow-up time of 6.1 years (IQR: 4.1) sleep disturbances were reported by 32.3% of male and
48.4% of female patients. During the observation period, 318 men (12.7%) and 131 women (15.8%) died. Men who
‘sometimes’ had sleep disturbances showed a 56% increased mortality risk compared to those without complaints in an
age-adjusted model (HR 1.56; 95%-CI 1.21–2.00). Additional adjustment for confounding variables attenuated the effect to
1.40 (95%-CI 1.08–1.81). Corresponding HRs among women were 0.97 (95%-CI 0.65–1.44) and 0.99 (95%-CI 0.66–1.49). HRs
for patients with nightly sleep disturbances did not suggest any association for both sexes.
Conclusions: Our study found that nightly sleep disturbances have no influence on long-term survival in male and
female AMI patients. Contrary to women, men who reported sometimes sleep disturbances had a higher mortality.
Further investigations on this topic taking into account the role of obstructive sleep apnoea are needed.
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Background
Sleep disturbances rank as a relevant public health
problem in modern society and are expected to increase
in the future for several reasons, such as rising job
demands combined with 24/7 service availability,
inappropriate use of internet or mobile phones at night
and ageing populations [1]. Already, about one third of
the general population is affected by sleep disturbances
in terms of difficulties initiating sleep, maintaining sleep
or non-restorative sleep [2]. Sex differences regarding
the prevalence of reported insomnia symptoms were
shown in previous work and resulted in an estimated
female/male ratio of 1.4 which further increased with
age [2, 3]. Due to its regenerative function, sleep influ-
ences both physical and mental health outcomes.
Research in the last decades provided increasing
evidence for sleep disturbances - with respect to both
sleep quality and quantity - as a risk factor for cardiovas-
cular disease (CVD), cardiac death and all-cause
mortality [4–7].
While healthy populations were extensively studied in
this context, sleep-related investigations in acute myo-
cardial infarction (AMI) patients are rare. However, pre-
vious results indicated that sleep complaints might be
associated with disease progression and worse survival
prognosis after AMI. Heavy snoring, a proxy for
obstructive sleep apnea, was shown to precipitate pro-
gression of atherosclerosis in women with AMI or
unstable angina pectoris [8] and to be associated with an
increased case-fatality in AMI patients [9]. The associ-
ation between obstructive sleep apnea and risk of CV
events and death has been well established in earlier
studies [7, 10]. However, recent findings question the
impact of obstructive sleep apnea on CV outcomes [11].
Shah et al. [11] suggests a potential cardioprotective
effect of obstructive sleep apnea in AMI patients due to
ischemic preconditioning. Regarding sleep duration,
patients with an acute coronary syndrome who slept less
than 7 h per night in the month after the event had an
50% elevated 1-year risk of acute coronary syndrome
recurrence and mortality compared to acute coronary
syndrome patients who reported longer sleep duration
[12]. To our knowledge, only two studies [13, 14] inves-
tigated the associations between difficulties initiating
sleep or disturbed sleep, respectively, and long-term out-
comes in AMI patients. While Condén & Rosenblad [13]
followed up recent AMI cases for all-cause mortality
without distinction between patients’ sex for the
analyses, Clark et al. [14] investigated a composite out-
come of incidence of or death from recurrent cardiovas-
cular events during a 10-year follow-up and additionally
used data originated from the early 90s.
Hence, the aim of our study was to examine the asso-
ciation of patient-reported sleep disturbances within 4
weeks before incident myocardial infarction (MI) and
long-term survival, separately for men and women, using
data from the percutaneous coronary intervention era.
Sleep disturbances in this study were not regarded as a
proxy for any sleep disorder but as a complaint
perceived by patients which may have an indicative value
for their long-term prognosis.
Methods
Data for the present observational study stemmed from
the population-based MONICA/KORA MI registry in
Augsburg (Southern Bavaria, Germany). The study area
comprised a total of about 600,000 inhabitants and eight
cooperating hospitals. From the beginning in 1984, all
cases of coronary deaths and non-fatal MIs of the study
population, aged 25–74 years and resident in the study
area, have been continuously documented in the registry.
Methods of case identification, diagnostic classification
of events, and data quality control have been described
in detail elsewhere [15, 16]. Briefly, patients hospitalized
for AMI and having survived for at least 24 h after
hospitalization were interviewed by trained study nurses
after transfer from the intensive care unit. They
collected information on socio-demographic characteris-
tics, cardiovascular risk factors, medical history of MI,
stroke, comorbidities and information on the acute event
using a standardized questionnaire. Additional data on
AMI characteristics, treatment, in-hospital complica-
tions, comorbidities, vital status and discharge medica-
tion were provided by medical chart review.
Based on a total sample of 7115 registered patients
between January 1, 2000 and December 31, 2008, our
study question was confined to those who had first-time
AMI and survived for at least 28 days after the event
(n = 4423). We further excluded those without informa-
tion on sleep disturbances (n = 981) as well as patients
with missing data on relevant covariables to be included
in final regression models (n = 103), leaving 2511 men
and 828 women eligible for the analyses of long-term
survival (Fig. 1). Patients with missing values on sleep
disturbances had a worse prognosis compared to those
with available data (crude Hazard Ratio (HR) for
long-term mortality 2.72; 95% confidence interval (CI):
2.29–3.22 (men) and HR 2.14; CI 1.62–2.83 (women)).
In most cases, sleep information was lacking because no
interview was conducted (96.6%).
Information on sleep disturbances was collected by
one questionnaire item. ‘How often did you suffer from
sleep disturbances within the last 4 weeks?’ could be
answered by the response categories ‘1: never’, ‘2: less
than once per week’, ‘3: once per week’, ‘4: more than
once per week’, ‘5: every night’, ‘6: I do not know’. Patients
who indicated the latter (n = 42) were treated as cases
with missing data. For the 3-categorical primary
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Fig. 1 Flow chart of study sample selection
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independent variable ‘frequency of sleep disturbances’,
we summarized answers to ‘never’ (original category 1),
‘sometimes’ (original categories 2–4) and ‘every night’
(original category 5) assuming that patients suffering not
at all (1) or nightly (5) would rate themselves rather
accurately.
The following covariables were captured and consid-
ered for analysis: patients were asked whether they were
employed (currently, formerly, never), whether they were
married (yes/no) and whether they smoked (currently,
formerly, never). The highest acquired school-leaving
qualification was captured to evaluate educational level
(according to the German school system: 1 = lower
secondary school; 2 = secondary school; 3 = high school
diploma; 4 = university degree; 5 = other qualification; 6
= refused to reply). This information was dichotomized
for analysis as ‘low education (< 9 years)’ which corre-
sponds to response category 1 (yes/no). Body mass index
(BMI) was obtained by assessment of height and weight
during the hospital stay and adiposity was defined as
BMI > 30 kg/m2 (yes/no). While the history of stroke
(yes/no) was only determined by self-report, medical his-
tory of angina pectoris, hypertension, hyperlipidemia or
diabetes (yes/no) was considered if confirmed by chart
review. The type of AMI was defined as ST-segment ele-
vation MI (STEMI), Non-ST-segment elevation MI
(NSTEMI), bundle branch block, or non-classifiable/
missing. The latter two categories were summarized to
‘non-classifiable’ for analysis. Regarding primary care,
revascularization therapy (yes/no) was defined as having
received thrombolysis, percutaneous transluminal coron-
ary angioplasty with or without stenting or coronary
artery bypass surgery. A combination of the following
four evidence based medications is strongly recom-
mended as standard of care after AMI with reported
benefit on long-term survival: anti-platelet agents,
beta-blockers, statins and angiotensin-converting
enzyme inhibitors or angiotensin-receptor blockers [17].
Thus, we summarized data on medication at hospital
discharge to treatment with all 4 evidence based medica-
tions (yes/no).
The outcome of interest was all-cause mortality, assessed
by checking the vital status of all recorded persons in the
MI registry. Local health departments inside and addition-
ally outside the study region were involved in the mortality
follow-up assessment, which takes place about every 5
years, in order to ascertain the survival status of all partici-
pants including those who had moved out of the study area.
Follow-up for this study ended in December 2011. Survival
time was measured in days and defined from day of the
acute event to the day of death. Patients who were still alive
at the end of the follow-up period were censored.
Analyses were done separately for men and women
due to differences in CVD risk profile and outcome [18]
and differences in both their reported [3] and objective
sleep habits [19, 20], comparable to previous investiga-
tions [14]. The primary independent variable was
cross-tabulated with potential covariables. Categorical
ones were presented as absolute numbers and percent-
age, and evaluated for differences in frequency distribu-
tion with χ2-test. Continuous data was expressed as
median with interquartile range (IQR) and compared
using Kruskal-Wallis test as non-parametric equivalent
to one-way analysis of variance.
Differences in survival time were determined by
Log-Rank test for all categorical variables or simple Cox
regression models for continuous age and BMI,
respectively.
Except for age, which was a priori determined to be
forced in regression models, only those variables were
considered for subsequent regression modeling which
were significantly associated with either sleep distur-
bances or long-term survival in sex-specific
comparisons.
Kaplan-Meier-curves were generated for the primary
independent variable. Differences in survival time
between the three strata of the primary independent
variable were determined by log rank test. To estimate
the magnitude of impact of sleep disturbances on
all-cause mortality, several Cox proportional hazard
regression models were fitted. Hazard ratios were pre-
sented with 95%- confidence intervals and patients never
having suffered from sleep disturbances within 4 weeks
prior to AMI as reference category. The overall influ-
ence of the 3-categorical primary independent variable
was evaluated using Likelihood-Ratio tests. First, univari-
able regression models were calculated for men and
women to assess the crude association followed by
age-adjusted models. Minimally adjusted models were
then individually expanded for covariables sets from the
domains socio-demographic/lifestyle, comorbidities and
clinical aspects. Finally, a full model - identical for both
sexes - was fitted containing all covariables with either
significant association in the male or female data set. To
control for possible cohort effects, the year of AMI was
also included. The potential mediating role of hyperten-
sion and diabetes [21, 22] on the association of sleep dis-
turbances and long-time mortality was considered by
refitting the full models without these variables.
Proportional hazards assumption was checked graph-
ically (parallel lines of log (−log(survival)) versus log of
survival times) for all variables. In case of violating the
proportional hazards requirement, a time-dependent
variable was created for the respective variable and
tested in a bivariate cox regression model for statistical
significance. Solely the interaction terms for age and
BMI with log (survival) in the female group were statisti-
cally significant. Since HRs for the primary independent
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variable hardly changed when time-dependent variables
were included, we decided to report the results for the
simple models without interaction terms.
Interaction effects of age with sleep disturbances were
tested in bivariate and full models, but failed to reach
statistical significance.
To account for the arbitrary categorization of the
primary independent variable, sensitivity analyses were
performed with the following two alternative categoriza-
tions in age-adjusted and full models: 1) another
3-categorical allocation (never [original category 1],
occasionally [original categories 2, 3], frequently [original
categories 4, 5]) and 2) a binary classification (any sleep
disturbances in the prior 4 weeks yes [1]/ no [2–5]). In
further sensitivity analyses, we restricted the male study
population to those patients with normal weight (BMI
≥18.5 and < 25 kg/m2), in order to consider potential
confounding through obstructive sleep apnea, which
occurs more often in overweight men [23]. Finally, crude
and age-adjusted models were refitted including also
patients with missing data on any of the covariates of
the full model.
For all investigations, a significance level of 5% was
applied. Data management and analysis were performed
using SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina).
Results
The study sample consisted of 2511 male and 828 female
patients. With a median age of 65 years (IQR: 12)
women were older than men (60 (IQR: 15)) and more
often diagnosed with hypertension and diabetes.
Baseline socio-demographic data, lifestyle factors,
comorbidities, AMI and treatment characteristics of
male and female patients stratified by frequency of sleep
disturbances are presented in Table 1. Almost 50% of
female patients indicated having been affected by sleep
disturbances anytime (30.3% sometimes and 18.1%
nightly) whereas about 30% of the male sample reported
sleep disturbances preceding AMI (22.7 and 9.6%,
respectively). These numbers changed in the course of
the study period starting with a proportion of 35% of
women in the year 2000 up to almost 60% 8 years later.
An even stronger increase from early 18% to later 48%
reporting any sleep disturbance was observed for men.
Median age did not significantly vary across categories
of sleep disturbances for both sexes. Overall, none of the
analyzed variables were significantly associated with fre-
quency of sleep disturbances in female patients, but for
men some differences were detected. Among others,
BMI of men was slightly, but significantly, different in
the sleep categories with the highest median value in the
‘nightly’ group (27.7, IQR: 5.3). The proportion of male
hypertensive patients increased with frequency of sleep
complaints from 71.8 to 80.1%. The same trend applied
to patients diagnosed with angina pectoris. Regarding
revascularization therapy, male patients in the bottom as
well as in the upper sleep category more often received
any of the mentioned treatments.
Median follow-up time was 6.1 years in men and
women (IQR: 4.1). Overall, women had a greater
long-term mortality rate than men (26 vs. 21 deaths per
1000 person years, respectively). For men, the highest
mortality rate was observed for patients who sometimes
suffered from sleep disturbances (28 deaths per 1000
person years vs. 19 and 18 deaths per 1000 person years
for the bottom and upper category, respectively) while
the mortality rate for females did not differ between cat-
egories. Kaplan-Meier survival curves visualizing these
tendencies in Fig. 2 demonstrated significant differences
in survival according to frequency of sleep disturbances
for men (Log-Rank, p = 0.0014), but not for women
(Log-Rank, p = 0.9690).
Results from Cox regression analyses are presented in
Table 2. The age-adjusted model for men revealed a 56%
increased all-cause mortality risk for patients who some-
times suffered from sleep disturbances compared to
those reporting no sleep disturbances (HR 1.56; 95%-CI
1.21–2.00) whereas male patients who indicated having
had disturbed sleep every night did not show an elevated
relative risk (HR 1.00; 95%-CI 0.66–1.51). By separately
adding covariables sets from the domains ‘socio-demo-
graphic/lifestyle’, ‘comorbidities’, and ‘clinical aspects’ to
the age-adjusted model, HRs hardly changed. The
decrease of HR [sometimes vs. never] by 5.8% was great-
est for the model ‘Clinical’ and mainly explained by
revascularization treatment. The full model finally atten-
uated the long-term mortality risk for the second
category to 1.40 (HR, 95%-CI 1.08–1.81). However, the
increase remained significant as well as the overall
impact of sleep disturbances (Likelihood-Ratio Test p =
0.0370).
For women, a relation between sleep disturbances
prior to AMI and long-term mortality was detected
neither in the age-adjusted or subset models nor in the
full model controlled for the same confounders as used
in the male model.
When the potential mediator variables hypertension
and diabetes were removed individually and together
from the full model, HR estimates for sleep disturbances
did not change remarkably both for men and women
(data not shown).Table 3 summarizes the distribution of
the study sample depending on the respective
categorization of frequency of sleep disturbances. As
sensitivity analysis we refitted the age-adjusted and full
model for males and females with alternative categoriza-
tions of the primary independent variable. Results of the
regression models are shown in Table 4. For the other
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3-level variable (categorization 2), the influence of sleep
disturbances on long-term mortality in male AMI
patients lost overall significance (Likelihood-Ratio Test
p = 0.1254). Likewise, the binary comparison failed to
reach statistical significance (HR 1.26; 95% CI 1.00–1.60,
p = 0.0543). Again, for women no associations were
observed.
The association of sleep disturbances and all-cause
mortality was not seen any more in the full model
restricted to the 629 male patients with normal
weight (HR [sometimes vs. never] 1.16, 95%-CI 0.72–
1.88 and HR [nightly vs. never] 1.48, 95%-CI 0.76–
2.88).
In a final sensitivity analysis, adding the patients with
missing data on any covariables of the full model (add-
itionally 82 males and 21 females), no notable changes
regarding the unadjusted and age-adjusted HRs resulted
(data not shown).
Discussion
In our study, we found a 40% increased long-term
mortality risk in the fully adjusted model for male AMI
patients who sometimes, i.e. up to several times a
week, suffered from sleep disturbances within 4 weeks
before the acute event. For men with nightly sleep
disturbances and for women, however, no associations
between sleep disturbances and long-term mortality
were seen in our data.
Overall, sleep disturbances were reported by 36.3% of
our total sample of AMI patients, which is somewhat
higher than referred for the general population [2]. The
proportion was considerably larger in women than in
Table 1 Sample characteristics for male and female AMI patients stratified by frequency of sleep disturbances
Men (n = 2511) Women (n = 828)














Age, years [median (IQR)] 60 (15) 60 (15) 60 (14) 0.7213 65 (13) 65 (13) 65 (12) 0.8775
Low Education, < 9 years 1186 (69.8) 407 (71.3) 170 (70.5) 0.7958 351 (82.2) 202 (80.8) 113 (75.3) 0.1894
Married 1378 (81.1) 435 (76.2) 190 (78.8) 0.0375 258 (60.42) 147 (58.57) 91 (60.67) 0.8732
Currently employed 788 (46.4) 243 (42.6) 99 (41.1) 0.1236 98 (22.95) 50 (19.92) 26 (17.33) 0.3057
Lifestyle factors
BMI, kg/m2 [median (IQR)] 27.1 (4.8) 27.4 (4.7) 27.7 (5.3) 0.0370 26.8 (7.4) 27.5 (7.1) 27.7 (7.0) 0.5334
Adiposity, BMI > 30 kg/m2 376 (22.1) 141 (24.7) 69 (28.6) 0.0566 134 (31.4) 86 (34.3) 50 (33.3) 0.7258
Ever Smoker 1280 (75.3) 402 (70.4) 187 (77.6) 0.0322 209 (49.0) 112 (44.6) 76 (50.7) 0.4216
Comorbidities
Angina 190 (11.2) 104 (18.2) 52 (21.6) < 0.0001 69 (16.16) 30 (11.95) 31 (20.67) 0.0631
Hypertension 1219 (71.8) 438 (76.7) 193 (80.1) 0.0040 350 (82.0) 206 (82.1) 129 (86.0) 0.5034
Dyslipidemia 1220 (71.8) 394 (69.0) 172 (71.4) 0.4393 310 (72.6) 187 (74.5) 119 (79.3) 0.2665
Diabetes 443 (26.1) 143 (25.0) 59 (24.5) 0.8022 137 (32.1) 82 (32.7) 53 (35.3) 0.7647
Stroke 75 (4.4) 29 (5.1) 15 (6.2) 0.4232 28 (6.6) 15 (6.0) 14 (9.3) 0.4070
Clinical aspects
Type of Infarction
STEMI 710 (41.8) 204 (35.7) 86 (35.7) 0.0756 180 (42.2) 87 (34.7) 64 (42.7) 0.2622
NSTEMI 872 (51.3) 323 (56.6) 137 (56.9) 229 (53.6) 149 (59.4) 81 (54.0)
Bundle Branch Block/non-classifiable 117 (6.9) 44 (7.7) 18 (7.5) 18 (4.2) 15 (6.0) 5 (3.3)
Revascularization therapy 1521 (89.5) 490 (85.8) 221 (91.7) 0.0175 338 (79.2) 195 (77.7) 111 (74.0) 0.4254
4 EBM at discharge 1221 (71.9) 418 (73.2) 183 (75.9) 0.3852 285 (66.7) 180 (71.7) 111 (74.0) 0.1699
Mortality
Deceased during follow-up 206 (12.1) 87 (15.2) 25 (10.4) 0.0818 71 (16.6) 37 (14.7) 23 (15.3) 0.7964
Data is presented as absolute number (%) unless otherwise indicated.
AMI acute myocardial infarction, BMI Body Mass Index, EBM evidence based medication, IQR interquartile range, NSTEMI Non-ST-segment elevation myocardial
infarction, STEMI ST-segment elevation myocardial infarction
ap-values are obtained from χ2-tests for categorical data or from Kruksal-Wallis test for continuous data (age and BMI)
Nairz et al. BMC Cardiovascular Disorders          (2018) 18:235 Page 6 of 12
men (48.4% vs. 32.3%). This was not surprising since
women are known to be more frequently affected by in-
somnia symptoms due to hormonal and physiological
differences as well as psychosocial factors [24]. Depres-
sion and anxiety disorders which are almost twice as
prevalent in women compared to men [25] and are asso-
ciated with sleep disturbances [26], represent a relevant
factor regarding the female predominance in insomnia
symptoms [20]. Moreover, prevalence of insomnia was
shown to increase in postmenopausal women compared
to premenopausal women [27]. With a median age of 65
years in our female study sample, the majority of women
could be assumed to be in postmenopausal phase.
Finally, sleep disturbances increase with age [2]. This
a
b
Fig. 2 12-year survival curves for male (a) and female (b) AMI patients stratified by frequency of sleep disturbances. Footnote: “Differences in
survival time between the three strata of the primary independent variable were determined by log rank test.”
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Table 2 Association of frequency of sleep disturbances within 4 weeks prior to AMI (categorization 1) and long-term mortality in
male and female patients
Men (n = 2511; 318 deaths) Women (n = 828; 131 deaths)
HR [95% CI] p-valuea HR [95% CI] p-valuea
Frequency of sleep disturbances
Unadjusted model never 1 Ref. 0.0024 1 Ref. 0.9686
sometimes 1.58 [1.23–2.03] 1.00 [0.67–1.49]
nightly 1.00 [0.66–1.52] 0.94 [0.59–1.51]
Age-adjusted model never 1 Ref. 0.0032 1 Ref. 0.9773
sometimes 1.56 [1.21–2.00] 0.97 [0.65–1.44]
nightly 1.00 [0.66–1.51] 0.96 [0.60–1.53]
Model Lifestyleb never 1 Ref. 0.0038 1 Ref. 0.9665
sometimes 1.55 [1.20–1.99] 0.96 [0.64–1.43]
nightly 0.99 [0.65–1.50] 0.95 [0.59–1.52]
Model Comorbiditiesc never 1 Ref. 0.0060 1 Ref. 0.9556
sometimes 1.50 [1.16–1.93] 0.98 [0.66–1.47]
nightly 0.92 [0.60–1.39] 0.93 [0.58–1.49]
Model Clinicald never 1 Ref. 0.0150 1 Ref. 0.9899
sometimes 1.47 [1.14–1.89] 0.97 [0.65–1.46]
nightly 1.02 [0.67–1.54] 0.97 [0.61–1.57]
Full modele never 1 Ref. 0.0370 1 Ref. 0.9055
sometimes 1.40 [1.08–1.81] 0.99 [0.66–1.49]
nightly 0.95 [0.62–1.45] 0.90 [0.55–1.46]
AMI = acute myocardial infarction, CI = confidence interval, HR = Hazard Ratio
ap-value obtained from Likelihood-Ratio test for overall significance of 3-categorical variable ‘frequency of sleep disturbances’ in the respective model
bMEN: adjusted for age (cont.), married, low education (< 9 years), employment status, smoking ever and BMI (cont)
WOMEN: adjusted for age (cont.), married and employment status
cMEN: adjusted for age (cont.), hypertension, angina, diabetes, dyslipidemia and stroke
WOMEN: adjusted for age, diabetes and stroke
dMEN: adjusted for age (cont.), type of infarction, any revascularization treatment (coronary artery bypass surgery, percutaneous coronary intervention (PCI) with/
without stenting, or thrombolysis), all four evidence based medications at discharge (antiplatelet agents, beta-blockers, ACEIs/ARBs (Angiotensin-converting
enzyme inhibitors/Angiotensin receptor blockers), statins) and year of MI
WOMEN: adjusted for age (cont.), type of infarction, any revascularization treatment and all four evidence based medications at discharge
eMEN AND WOMEN: adjusted for age (cont.), low education (< 9 years), married, employment status, ever smoking, BMI (cont.), hypertension, angina, diabetes,
dyslipidemia, stroke, type of infarction, any revascularization treatment, all four evidence based medications at discharge and year of MI
Table 3 Distribution of patients and events according to different categorizations of the primary independent variable
Frequency of sleep disturbances within 4
weeks prior to AMI
Men (n = 2511) Women (n = 828)
No. per category (%) No. of deaths No. per category (%) No. of deaths
Original response never 1699 (67.7) 206 427 (51.6) 71
< 1 per week 247 (9.8) 40 82 (9.9) 14
once per week 67 (2.7) 10 31 (3.7) 7
> 1 per week 257 (10.2) 37 138 (16.7) 16
nightly 241 (9.6) 25 150 (18.1) 23
Categorization 1 never 1699 (67.7) 206 427 (516) 71
sometimes 571 (22.7) 87 251 (30.3) 37
nightly 241 (9.6) 25 150 (18.1) 23
Categorization 2 never 1699 (67.7) 206 427 (51.6) 71
occasionally 314 (12.5) 50 113 (13.7) 21
frequently 498 (19.8) 62 288 (34.8) 39
Binary (any time) no 1699 (67.7) 206 427 (51.6) 71
yes 812 (32.3) 112 401 (48.4) 60
AMI acute myocardial infarction
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trend might also contribute to the difference in propor-
tions of reported sleep disturbances in our study, as
women were significantly older in the analyzed data.
Overall, unadjusted percentages of both men and
women who reported sleep disturbances in our study
clearly increased within the study period from the year
2000 to 2008 by factor 2.7 and 1.7 respectively. Previous
epidemiological studies in several countries presented
increasing prevalence of sleep complaints on population-
level in the last decades [28]. Among others, the
demographic change and growing health problems
such as the obesity epidemic were considered as reasons
for this development as well as altering occupational
requirements such as shift-work and increased work-load
[1, 28]. Nevertheless, this trend might be at least in part
influenced by a sort of reporting bias due to growing
awareness for sleep problems.
Referring to the International Classification of Sleep
Disorders – 3rd edition [29] (ICSD-3) and the Diagnostic
and Statistical Manual of Mental Disorders – 5th edition
[30] (DSM-5) criteria for insomnia disorder, many studies
applied a frequency of at least three times per week to rate
sleep disturbances as symptomatic [2]. Transferred to our
data, 23.5% reported to have suffered from sleep distur-
bances several times a week or nightly, which corresponds
to category ‘frequently’ in categorization 2 (19.8% of men
and 34.8% of women, respectively). These numbers were
similar to those stated in two previous studies on the asso-
ciation of sleep disturbances prior to AMI with long-term
outcomes of patients [13, 14], but the assessment and def-
inition of sleep disturbances varied.
In the cohort study by Condén & Rosenblad [13]
23.9% of 732 Swedish AMI patients, recruited between
2006 and 2011, were classified as having insomnia,
which was defined in the study as difficulty falling asleep
without considering the frequency of occurrence (19.7%
of men and 32.7% of women, respectively). Further, the
corresponding question was not limited to the period
prior to the cardiovascular event and hence might also
have captured cases which had problems with initiating
sleep as a result of the MI. This could have influenced
the survival prognosis in the group of insomnia patients
who had an almost 60% elevated, multivariable adjusted,
all cause-mortality risk in the period after the first 2
years of follow-up (mean follow-up time 6.0 years) com-
pared to patients not having suffered from difficulties
falling asleep. Thus, the relative long-term mortality risk
for male and female insomnia patients in Condén &
Rosenblad [13] was higher than the fully adjusted HR
that we found for men who had sometimes suffered
from sleep disturbances (HR 1.40, 95%-CI 1.08–1.81) or
men who reported sleep disturbances at any time within
4 weeks prior to AMI (HR 1.26; 95%-CI 1.00–1.60).
In the second previous study investigating long-term
outcomes after AMI by Clark et al. [14] based on the
Stockholm Heart Epidemiology Program (SHEEP), sleep
impairment was assessed in more detail for 1089 male
and 499 female patients with first-time AMI between
Table 4 Association of frequency of sleep disturbances within 4 weeks prior to AMI (categorization 2 and binary split) and long-term
mortality in male and female patients
Men (n = 2511; 318 deaths) Women (n = 828; 131 deaths)
HR [95% CI] p-valuea HR [95% CI] p-valuea
Frequency of sleep disturbances
Age-adjusted model never 1 Ref. 0.0183 1 Ref. 0.7162
occasionally 1.52 [1.11–2.07] 1.12 [0.68–1.82]
frequently 1.29 [0.97–1.72] 0.90 [0.61–1.33]
Full modelb never 1 Ref. 0.1256 1 Ref. 0.7163
occasionally 1.37 [1.00–1.87] 1.10 [0.67–1.82]
frequently 1.19 [0.89–1.59] 0.89 [0.59–1.33]
Sleep disturbances at any time
Age-adjusted model no 1 Ref. 1 Ref.
yes 1.38 [1.10–1.74] 0.0070 0.96 [0.68–1.36] 0.8330
Full modelb no 1 Ref. 1 Ref.
yes 1.26 [1.00–1.60] 0.0571 0.95 [0.67–1.36] 0.7854
AMI acute myocardial infarction, CI confidence interval, HR Hazard Ratio
ap-value obtained from Likelihood Ratio test for overall significance of ‘frequency of sleep disturbances’ in the respective model
badjusted for age (cont.), low education (< 9 years), married, employment status, ever smoking, BMI (cont.), hypertension, angina, diabetes, dyslipidemia, stroke,
type of infarction, any revascularization treatment (coronary artery bypass surgery, percutaneous coronary intervention (PCI) with/without stenting, or
thrombolysis), all four evidence based medications at discharge (antiplatelet agents, beta-blockers, ACEIs/ARBs (Angiotensin-converting enzyme inhibitors/
Angiotensin receptor blockers), statins) and year of MI
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1992 and 1994. One of four sleep-related aspects was
disturbed sleep, which comprised items on general sleep
quality, difficulty falling asleep, repeated awakenings,
disturbed/uneasy sleep and premature awakenings. More
than 20% of the male patients and about one third of the
females reported to have experienced disturbed sleep.
Unlike in our interrogation, patients were asked for sleep
impairment within 1 year prior to initial AMI. Hence,
reported sleep disturbances might be more likely associ-
ated also with other health problems besides MI. A sig-
nificantly increased risk for incidence of or death from
cardiovascular events (distinguishing AMI [age-adjusted
HR 1.73; 95%-CI 1.03–2.91], stroke [multiple adjusted
HR 2.61; 95%-CI 1.19–5.76] or heart failure [multiple
adjusted HR 2.43, 95%-CI 1.18–4.97]) within a 10-year
follow-up was revealed for women but not for men with
disturbed sleep at least sometimes a week compared to
persons with less frequent or no complaints. As the end-
point of our study was all-cause mortality and we were
not able to consider recurrent cardiovascular events
after MI and cause-specific mortality, our results were
not comparable to the above mentioned study.
Within the framework of topic-related studies, the
results of our study therefore had to stand for them-
selves. We found an association of sometimes experi-
enced sleep disturbances and long-term all-cause
mortality in male AMI patients, but not in female
patients. Reasons for this sex difference can only be
speculative.
Firstly, sex differences in sleep architecture and in
implications of sleep disturbances might contribute to
the present results. Cross-sectional analyses of healthy
participants showed that the percentage of deeper slow
wave stage, which is important for regeneration during
sleep [31], was significantly lower in men across all age
groups and decreased in men getting older but not in
women [19, 32]. However, sleep continuity and archi-
tecture were shown to change when sleep complaints
became pathological. A recent meta-analysis showed a
significant reduction of slow wave and rapid eye move-
ment sleep in patients with primary insomnia com-
pared to a good sleeper control group [33]. How far the
above-mentioned sex differences hold also for people
complaining about sleep disturbances needs to be
examined. Secondly, one study found that healthy
women were more resilient to the consequences of ele-
vated circulating inflammatory markers induced by
sleep disturbances than healthy men [34]. If these
observations apply in a similar manner to a MI popula-
tion, women might cope better with the consequences
of sleep disturbances and thus repel a potential adverse
impact on long-term survival.
Thirdly, though women across all age strata subjectively
reported more sleep complaints than men [3], some studies
revealed no relative differences in polysomnography mea-
surements or even better objective sleep quality for women
[20, 24, 32]. Hence, we cannot fully rule out misclassifica-
tion of female patients as a consequence of misperception
of sleep-state to cause sex differences in long-term progno-
sis in our study and to obscure a potential association in
women.
Contrary to what one might expect, we also did not
detect an increased mortality risk for patients who suf-
fered nightly from sleep disturbances within 4 weeks pre-
ceding the AMI. This may be a result of fewer patients
in this category leading to insufficient power to reveal a
possible association. Another reason could be a change
in individual frequency of sleep disturbances during the
follow-up period, particularly as a consequence of the
AMI and its severity. As sleep disturbances were
assessed only once in our registry, we could not investi-
gate this aspect in our analysis. Adding those patients
who suffered more than once per week from disturbed
sleep to the nightly group (yielding category ‘frequently’
of categorization 2), did not reveal a significant increase
in mortality risk either. These sensitivity analyses, includ-
ing the binary comparison, question the robustness of
the observed association for male patients found for
categorization 1 and stress the need for further investiga-
tions. Another reason for our unexpected non-significant
result observed in patients who suffered nightly from
sleep disturbances might be driven by most resent litera-
ture on the role of chronic obstructive sleep apnea as a
pre-conditioning stimulus that may have cardioprotec-
tive effects in some AMI patients [11]. Shah et al.
[11] found a high prevalence (77%) of sleep disor-
dered breathing among patients with AMI and
observed that patients with obstructive sleep apnea
(35%) develop a less severe cardiac lesion than those
without obstructive sleep apnea. These findings ques-
tion the previous literature that found obstructive
sleep apnea to be an independent risk factor for fatal
and non-fatal CVD. Nightly sleep disorder caused by
non-treated obstructive sleep apnea may have influ-
enced our results and warrants further investigation.
As observational studies still varied widely in the defin-
ition of insomnia and other sleep complaints, future
research should draw profit from improvements and
assimilation of existing diagnostic classification systems of
sleep disorders and research diagnostic criteria for insomnia
[29, 30]. For this purpose, a harmonization of the assess-
ment of sleep disturbances in epidemiological research
would be helpful to yield comparable results and hence to
contribute to evident findings. Based on the recently revised
ICSD − 3 and DSM-5 criteria for insomnia, a commonly
accepted approach to assess sleep disturbances on a
population-level should at least specify the kind of symp-
toms to be captured, their frequency in a defined time
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period as well as their severity with regard to daytime
consequences.
To the best of our knowledge, the present study was
the first to examine associations of patient-reported
sleep disturbances shortly before AMI and long-term
all-cause mortality separately for men and women using
data from the percutaneous coronary intervention era.
A further strength of our study is the large sample from
a population-based MI registry with high quality and val-
idation standards contributing to the generalizability of
our results.
Finally, we were able to adjust for a number of poten-
tial confounders, comprising lifestyle factors, comorbidi-
ties and clinical aspects.
Nevertheless, some important potential confounders
were lacking. First, we were not able to adjust for
depressive symptoms though depression is known to be
associated with sleep disturbances [26] as well as cardio-
vascular outcomes and mortality [35].
Likewise, our study did not control for obstructive
sleep apnea which may have a confounding influence on
the relation between sleep disturbances and long-term
mortality after MI [7, 10]. To account for this issue we
did a sensitivity analysis in normal weight male patients,
as obstructive sleep apnea is more frequent in over-
weight men [23]. Sleep disturbances were not significant
anymore in the full model, but estimates resulted from a
markedly smaller patient group with only 11 events in
the category of nightly sleep disturbances and have to be
treated with caution. However, the aspect of weight was
not disregarded in the primary analysis as regression
models are adjusted for BMI.
Finally, data on sleep disturbances was based on
self-report in this study and resulted from only one
questionnaire item. However, in clinical practice no
objective sleep data will be available either and physi-
cians have to rely on compact patient information.
Nevertheless, sleep disturbances in our study were
uniquely assessed right after the AMI and we did not
know about frequency of sleep disturbances in the
follow-up period.
Conclusion
In summary, our data indicate that sleep disturbances were
more frequently reported in AMI patients over time with a
higher increasing prevalence observed in males. We found
an association of sometimes experienced sleep disturbances
and long-term all-cause mortality in male but not female
AMI patients. In patients who reported nightly sleep distur-
bances, we did not found a significant association. This
unexpected latter result and the sex-differences observed in
our study need further investigations considering the diag-
nosis and treatment of commonly reported obstructive
sleep apnea in AMI patients.
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